Company news

AbCellera Biologics Inc. news in 2026

AbCellera Biologics Inc.'s news releases, calls and decks from 2026, newest first.

View company

AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026

November 5, 2026

AbCellera to Present at Upcoming Investor Conferences in November 2026

October 22, 2026

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

October 8, 2026

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

October 1, 2026

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

September 16, 2026

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

September 2, 2026

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

August 13, 2026

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 11, 2026

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

August 10, 2026

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

August 7, 2026

Q2 2026 Business Update Presentation

August 5, 2026

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

July 29, 2026

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

July 7, 2026

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

July 6, 2026

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

June 5, 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

April 20, 2026

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

April 1, 2026

AbCellera Reports Full Year 2025 Business Results

February 24, 2026

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

February 11, 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

January 22, 2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

January 11, 2026

Calls in 2026

Decks in 2026